| Similar Articles |
|---|
 |
The Motley Fool
May 21, 2007
Mike Havrilla |
Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in.   |
The Motley Fool
May 13, 2004
Charly Travers |
Avoiding Biotech Land Mines Successful biotech investing depends upon not getting caught up in bad situations. Lessons learned from these case studies can help us from getting trapped in similar situations in the future. |
The Motley Fool
July 21, 2011
Brian Orelli |
AMAG-Allos, a Match Made in Necessity What do you get when you combine one unprofitable biotech, AMAG Pharmaceuticals, with another unprofitable biotech, Allos Therapeutics? |
BusinessWeek
February 9, 2004
Gene G. Marcial |
Telik's Promising Tumor Treatments Telik, which develops drugs for cancer -- mainly chemotherapy-resistant solid tumors -- and diabetes may be the next biotech buyout. So says Mark Monane of investment outfit Needham, who identified Esperion Therapeutics in early December as buyout bait. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM... |
The Motley Fool
December 9, 2009
Brian Orelli |
Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little. |
The Motley Fool
May 2, 2007
Mike Havrilla |
Heads Up, Biotech Investors: Chapter 2 Get to know the timing of major catalysts for stocks that may be on your biotech watch list. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
The Motley Fool
December 7, 2009
Brian Orelli |
When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
August 17, 2004
Charly Travers |
Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector. |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
June 2, 2004
W.D. Crotty |
FDA's Kiss of Life The FDA ignores its advisory committee and approves Allos' new drug. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
December 29, 2003
Gene G. Marcial |
Faster Pulse At Esperion Esperion Therapeutics shares may zip up, says Mark Monane of investment firm Needham. Pfizer, Genentech, or Aventis could strike a deal for any of Esperion's four cardiovascular drugs now in trials, he says. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research. |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
BusinessWeek
October 17, 2005
Gene G. Marcial |
Encysive Is Breathing Easy Among biotechs favored by Mark Monane of investment firm Needham is Encysive Pharmaceuticals. |
The Motley Fool
May 5, 2004
Charly Travers |
Growing Profits at Connetics A broad product line is leading to sustainable growth for the small drug developer. |
The Motley Fool
July 22, 2011
Anand Chokkavelu |
9 Small Biotechs Near 52-Week Lows Here are nine companies in this space that are within 20% of their 52-week lows and have market caps between roughly $200 million and $500 million. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
